$4,599.90 travel Payment -- Regeneron Pharmaceuticals to Dr. Christine Edwards

Regeneron Pharmaceuticals covers travel and lodging for Dermatology's Dr. Edwards related to Ibrance.

This page provides a detailed analysis of a $4,599.90 travel payment from Regeneron Pharmaceuticals to Dr. Christine Edwards. Data is from the CMS Open Payments (Sunshine Act) database.

Payment Details

FieldValue
Amount$4,599.90
Payment Typetravel
Payment NatureTravel and Lodging
Pharmaceutical CompanyRegeneron Pharmaceuticals
PhysicianDr. Christine Edwards
NPI Number1902677939
Physician SpecialtyDermatology
LocationSan Jose, CA
Date of Payment2024-06-06
Related Drug/DeviceIbrance
Conflict AssessmentModerate -- Worth Noting

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Regeneron Pharmaceuticals made a $4.6K travel payment to Christine Edwards, a Dermatology specialist in San Jose, CA. The payment was associated with Ibrance. Regeneron Pharmaceuticals paid $4,599.90 for travel and lodging expenses for Dr. Christine Edwards. The payment was associated with the drug Ibrance. This payment occurred on June 6, 2024, in San Jose, CA.

Patient Guidance: What This Payment Means for You

This payment may cover travel and lodging expenses related to professional development or educational events concerning medications. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Travel and lodging payments are common in pharmaceuticals, but the specific context for dermatology related to Ibrance would require further investigation.

Regulatory Context: Sunshine Act Requirements

Payments for travel and lodging are reportable under the Sunshine Act and are subject to disclosure to ensure transparency in physician-pharma relationships.

Related Topics

This payment is related to the following healthcare transparency topics:

Understanding travel Payments

Travel and lodging payments cover transportation and accommodation expenses for physicians attending conferences, advisory board meetings, or speaking engagements sponsored by pharmaceutical companies. These payments can be substantial, particularly for international travel or multi-day events.

Frequently Asked Questions About This Payment

What was this $4.6K payment for?

This was a travel payment of $4.6K from Regeneron Pharmaceuticals to Christine Edwards, categorized as "Travel and Lodging". It was associated with Ibrance. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Christine Edwards accept pharmaceutical money?

Yes, Christine Edwards received this $4.6K payment from Regeneron Pharmaceuticals. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Christine Edwards's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this travel payment?

A travel payment of $4.6K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Dermatology?

To compare this payment against Dermatology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Dermatology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Christine Edwards's relationship with Regeneron Pharmaceuticals?

The payment covers travel and lodging, indicating potential educational or informational activities. This $4.6K travel payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Dermatology?

The amount is moderate, suggesting a single or short-term event.

What should patients do after learning about this payment?

This payment may cover travel and lodging expenses related to professional development or educational events concerning medications.

What else should I know about this travel payment?

The payment is linked to Ibrance, a cancer medication.

Related Reports

Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.